SNN
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Smith & Nephew plc
- Nom
- Smith & Nephew plc
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $13.0B
- Employés
- 18,362
- PDG
- Deepak S. Nath
- Site web
- https://www.smith-nephew.com
- Marché
- ATECCNMDENOVGMEDIARTKIDS
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-06-17 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-09 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2023-07-10 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2022-09-02 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-09-02 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-05-05 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-05-05 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2021-12-14 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2021-02-26 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2021-02-26 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2018-10-17 | Thomas Charles MacArthur | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
SNN demonstrates solid financial recovery with improving margins and cash flow (liquidity score: 80, fundamentals trend: 75), but the absence of any meaningful event-driven catalyst (score: 25, type: NONE) severely…
The first sentence of the analysis written for SNN on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.57 · operating margin 13%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 68.3% | 70.2% | 70.2% | 70.9% | 71.0% | |
| Ebit Margin | 14.2% | 15.2% | 13.4% | 12.6% | 13.7% | |
| Ebitda Margin | 21.7% | 23.0% | 21.9% | 22.1% | 23.4% | |
| Operating Profit Margin | 12.9% | 11.3% | 7.7% | 8.6% | 11.4% | |
| Pretax Profit Margin | 12.6% | 8.6% | 5.2% | 4.5% | 11.2% | |
| Continuous Operations Profit Margin | 10.1% | 7.1% | 4.7% | 4.3% | 10.1% | |
| Net Profit Margin | 10.1% | 7.1% | 4.7% | 4.3% | 10.1% | |
| Bottom Line Profit Margin | 10.1% | 7.1% | 4.7% | 4.3% | 10.1% | |
| Current Ratio | 2.572 | 2.888 | 1.775 | 2.248 | 2.076 | |
| Quick Ratio | 1.245 | 1.329 | 0.720 | 0.963 | 1.211 | |
| Solvency Ratio | 0.210 | 0.169 | 0.154 | 0.152 | 0.193 | |
| Cash Ratio | 0.349 | 0.404 | 0.133 | 0.204 | 0.605 | |
| Price To Earnings Ratio | 22.473 | 26.149 | 22.733 | 53.780 | 28.850 | |
| Price To Earnings Growth Ratio | 0.406 | -1.207 | 0.162 | -0.922 | 1.635 | |
| Forward Price To Earnings Growth Ratio | 0.406 | -1.207 | 0.162 | -0.922 | 1.635 | |
| Price To Earnings Diluted Ratio | 22.785 | 26.149 | 22.733 | 53.780 | 28.850 | |
| Price To Earnings Diluted Growth Ratio | 0.428 | -1.207 | 0.162 | -0.922 | 1.635 | |
| Price To Book Ratio | 2.689 | 2.046 | 1.139 | 2.237 | 2.726 | |
| Price To Sales Ratio | 2.307 | 1.854 | 1.071 | 2.256 | 2.913 | |
| Price To Free Cash Flow Ratio | 16.691 | 17.778 | 32.819 | 106.961 | 32.369 | |
| Price To Operating Cash Flow Ratio | 11.066 | 10.915 | 9.770 | 25.140 | 17.310 | |
| Debt To Assets Ratio | 0.318 | 0.321 | 0.309 | 0.288 | 0.306 | |
| Debt To Equity Ratio | 0.629 | 0.631 | 0.591 | 0.546 | 0.600 | |
| Debt To Capital Ratio | 0.386 | 0.387 | 0.372 | 0.353 | 0.375 | |
| Long Term Debt To Capital Ratio | 0.364 | 0.372 | 0.294 | 0.328 | 0.327 | |
| Financial Leverage Ratio | 1.977 | 1.967 | 1.914 | 1.895 | 1.961 | |
| Working Capital Turnover Ratio | 2.284 | 2.499 | 2.846 | 2.352 | 1.978 | |
| Operating Cash Flow Ratio | 0.806 | 0.645 | 0.268 | 0.273 | 0.412 | |
| Operating Cash Flow Sales Ratio | 0.208 | 0.170 | 0.110 | 0.090 | 0.168 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.663 | 0.614 | 0.298 | 0.235 | 0.535 | |
| Debt Service Coverage Ratio | 5.269 | 8.214 | 1.409 | 5.960 | 2.247 | |
| Interest Coverage Ratio | 5.618 | 4.378 | 3.207 | 5.628 | 7.413 | |
| Short Term Operating Cash Flow Coverage Ratio | 15.482 | 493.500 | 0.856 | 4.216 | 2.016 | |
| Operating Cash Flow Coverage Ratio | 0.386 | 0.297 | 0.197 | 0.163 | 0.263 | |
| Capital Expenditure Coverage Ratio | 2.968 | 2.591 | 1.424 | 1.307 | 2.150 | |
| Dividend Paid And Capex Coverage Ratio | 1.684 | 1.394 | 0.806 | 0.683 | 1.190 | |
| Dividend Payout Ratio | 0.528 | 0.794 | 1.243 | 1.466 | 0.628 | |
| Enterprise Value Multiple | 12.717 | 10.094 | 7.185 | 12.424 | 14.134 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 68.2% | ▼-2.0% | ▼-1.9% |
| Ebit Margin | 14.2% | ▼-1.0% | ▲0.4% |
| Ebitda Margin | 21.7% | ▼-1.3% | ▼-0.7% |
| Operating Profit Margin | 12.9% | ▲1.6% | ▲2.5% |
| Pretax Profit Margin | 12.6% | ▲4.1% | ▲4.2% |
| Continuous Operations Profit Margin | 10.1% | ▲3.0% | ▲2.9% |
| Net Profit Margin | 10.1% | ▲3.0% | ▲2.9% |
| Bottom Line Profit Margin | 10.1% | ▲3.0% | ▲2.9% |
| Current Ratio | 2.572 | ▼-0.315 | ▲0.261 |
| Quick Ratio | 1.245 | ▼-0.083 | ▲0.152 |
| Solvency Ratio | 0.210 | ▲0.041 | ▲0.034 |
| Cash Ratio | 0.349 | ▼-0.055 | ▲0.010 |
| Price To Earnings Ratio | 22.473 | ▼-3.676 | ▼-8.324 |
| Price To Earnings Growth Ratio | 0.406 | ▲1.613 | ▲0.391 |
| Forward Price To Earnings Growth Ratio | 0.406 | ▲1.613 | ▲0.391 |
| Price To Earnings Diluted Ratio | 22.785 | ▼-3.364 | ▼-8.075 |
| Price To Earnings Diluted Growth Ratio | 0.428 | ▲1.635 | ▲0.409 |
| Price To Book Ratio | 2.689 | ▲0.642 | ▲0.521 |
| Price To Sales Ratio | 2.307 | ▲0.453 | ▲0.227 |
| Price To Free Cash Flow Ratio | 16.691 | ▼-1.087 | ▼-24.633 |
| Price To Operating Cash Flow Ratio | 11.066 | ▲0.151 | ▼-3.774 |
| Debt To Assets Ratio | 0.318 | ▼-0.003 | ▲0.010 |
| Debt To Equity Ratio | 0.629 | ▼-0.002 | ▲0.030 |
| Debt To Capital Ratio | 0.386 | ▼-0.001 | ▲0.012 |
| Long Term Debt To Capital Ratio | 0.364 | ▼-0.008 | ▲0.027 |
| Financial Leverage Ratio | 1.977 | ▲0.011 | ▲0.034 |
| Working Capital Turnover Ratio | 2.284 | ▼-0.216 | ▼-0.108 |
| Operating Cash Flow Ratio | 0.806 | ▲0.161 | ▲0.325 |
| Operating Cash Flow Sales Ratio | 0.208 | ▲0.039 | ▲0.059 |
| Free Cash Flow Operating Cash Flow Ratio | 0.663 | ▲0.049 | ▲0.194 |
| Debt Service Coverage Ratio | 5.269 | ▼-2.945 | ▲0.649 |
| Interest Coverage Ratio | 5.618 | ▲1.240 | ▲0.369 |
| Short Term Operating Cash Flow Coverage Ratio | 15.482 | ▼-478.018 | ▼-87.732 |
| Operating Cash Flow Coverage Ratio | 0.386 | ▲0.089 | ▲0.125 |
| Capital Expenditure Coverage Ratio | 2.968 | ▲0.377 | ▲0.880 |
| Dividend Paid And Capex Coverage Ratio | 1.684 | ▲0.290 | ▲0.533 |
| Dividend Payout Ratio | 0.528 | ▼-0.266 | ▼-0.404 |
| Enterprise Value Multiple | 12.717 | ▲2.623 | ▲1.407 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $14.22B | $10.77B | $5.94B | $11.77B | $15.18B | |
| Enterprise value | $16.99B | $13.48B | $8.72B | $14.29B | $17.23B | |
| EV / Sales | 2.76x | 2.32x | 1.57x | 2.74x | 3.31x | |
| EV / Op. cash flow | 13.22x | 13.65x | 14.35x | 30.53x | 19.65x | |
| EV / Free cash flow | 19.94x | 22.24x | 48.19x | 129.89x | 36.74x | |
| EV / EBITDA | 12.72x | 10.09x | 7.18x | 12.42x | 14.13x | |
| Net debt / EBITDA | 2.07x | 2.02x | 2.29x | 2.19x | 1.68x | |
| Current ratio | 2.57x | 2.89x | 1.77x | 2.25x | 2.08x | |
| Income quality | 2.06x | 2.40x | 2.31x | 2.10x | 1.67x | |
| Graham number | $10 | $8 | $13 | $6 | $9 | |
| Graham net-net | -$6 | -$5 | -$11 | -$6 | -$6 | |
| Tax burden | 80.2% | 82.7% | 90.7% | 94.9% | 89.4% | |
| Interest burden | 88.8% | 56.2% | 39.1% | 35.7% | 82.3% | |
| Working capital | $2.51B | $2.89B | $1.76B | $2.14B | $2.29B | |
| Invested capital | $8.14B | $8.37B | $7.33B | $7.86B | $8.19B | |
| Return on assets | 6.0% | 4.0% | 2.6% | 2.2% | 4.8% | |
| Operating ROA | 7.6% | 6.5% | 4.3% | 4.3% | 5.4% | |
| Return on tangible assets | 9.7% | 6.5% | 4.5% | 3.9% | 8.0% | |
| Return on equity | 11.8% | 7.8% | 5.0% | 4.2% | 9.4% | |
| Return on invested capital | 7.1% | 6.1% | 4.5% | 5.1% | 5.7% | |
| Return on capital employed | 9.0% | 7.4% | 5.5% | 5.5% | 6.7% | |
| Earnings yield | 4.4% | 3.8% | 4.4% | 1.9% | 3.5% | |
| Free cash flow yield | 6.0% | 5.6% | 3.0% | 0.9% | 3.1% | |
| Capex / Op. cash flow | 33.7% | 38.6% | 70.2% | 76.5% | 46.5% | |
| Capex / Depreciation | 75.6% | 68.6% | 81.0% | 65.3% | 72.5% | |
| Capex / Sales | 7.0% | 6.6% | 7.7% | 6.9% | 7.8% | |
| SG&A / Sales | 49.3% | 50.0% | 51.1% | 51.9% | 50.6% | |
| R&D / Sales | 5.6% | 5.9% | 6.1% | 6.6% | 6.8% | |
| Stock comp / Sales | 0.7% | 0.7% | 0.7% | 0.8% | 0.8% | |
| Intangibles / Total assets | 38.2% | 39.2% | 41.1% | 42.8% | 40.2% | |
| Days sales outstanding | 85d | 76d | 70d | 72d | 68d | |
| Days payables outstanding | 216d | 228d | 224d | 248d | 251d | |
| Operating cycle | 479d | 579d | 598d | 603d | 513d | |
| Cash conversion cycle | 263d | 351d | 374d | 355d | 261d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS), que se celebrará en Oporto (Portugal) del 8 al 10 de octubre.
- 2026-10-06 Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l''innovativo impianto per la riparazione della cartilagine, che sarà presentato all''ICRS Summit in Portogallo. Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l''innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all''International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall''8 al 10 ottobre.
- 2026-10-06 Smith+Nephew''s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week''s International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal from October 8-10.
- 2026-09-30 Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
- 2026-09-25 Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell? Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $27.05 and last traded at $27.0610, with a volume of 130820 shares traded. The stock had previously closed at $27.50. Wall Street Analysts Forecast Growth Several analysts recently issued reports on
- 2026-09-23 MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5 EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures.
- 2026-09-23 Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5 EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures.
- 2026-09-21 Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies: TENDON SEAM Rotator Cuff Repair System Recently acquired by Smith+Nephew, the TENDON SEAM System is a unique rotator cuff repair solution that offers superior load sharing designed to maximize repair strength throughout the healing period.1-4,*,** The construct features multiple tightly spaced 2x10mm anchors connected by a continuous stitch designed to distribute forces across the repaired tendon with a seam of fixation perpendicular to the direction of load.
- 2026-09-16 Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company''s 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer was made upon and is subject to the terms and conditions set forth in the Offer to Purchase.
- 2026-09-15 Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the pricing of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company''s 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer is made upon and is subject to the terms and conditions set forth in the Offer to Purchase.